BCL2 and acute myeloid leukemia: The BCL-2 selective inhibitor venetoclax (ABT-199) has shown efficacy in different hematological malignancies such as chronic lymphocytic leukemia (CLL) [11], acute myeloid leukemia (AML) [12] and T-cell acute lymphoblastic leukemia [13].